Get startedLog in
    Picture of Ensysce Biosciences logo

    ENSC — Ensysce Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Ensysce Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

    Picture of Ensysce Biosciences logoEnsysce Biosciences
    16/05/2025 14:31
    Ensysce Biosciences Inc ENSC.OQ reported a quarterly adjusted loss of $1.39​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-8.25.  The mean expectation of two analysts for the quarter was for a loss of $3.01 per share. Wall Street expected results to range from $-4.50 to $-1.53 per share.

Revenue rose 331.7% to $1.32 million from a year ago; analysts expected zero.

Ensysce Biosciences Inc's reported EPS for the quarter was a loss of $1.39​.

Ensysce Biosciences Inc shares had fallen by 16.4% this quarter and lost 73.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

Wall Street's median 12-month price target for Ensysce Biosciences Inc is $26.23

This summary was machine generated from LSEG data May 16 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)


    QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
    Mar. 31 2025-3.01-1.39Beat
    Dec. 31 2024-2.73-2.90Missed
    Sep. 30 2024-4.421.05Beat
    Jun. 30 2024-5.85-3.30Beat

    Recent news on Ensysce Biosciences

    See all news